Abstract:1122 Genetic polymorphisms in drug-metabolizing genes have been suggested to play an important role in the inter-individual variations in response to chemotherapy among cancer patients. Limited previous studies, most of which had a small sample size and evaluated a single gene effect on clinical outcomes of treatment, have produced inconsistent results. In this study, we evaluated a combined effect of functional polymorphisms in genes encoding five drug-detoxifying enzymes (GSTM1, GSTT1, GSTP1, UGT1A1 and SULT1A1) on overall survival among 951 breast cancer patients who were recruited into the Shanghai Breast Cancer Study during 1996-1998, treated with both surgery and chemotherapy, and genotyped for all five gene polymorphisms. Of them, 148 were deceased during a median follow-up of 5.2 years after diagnosis. The Cox regression model was used to assess the genotype-outcome association. With the exception of GSTP1 polymorphism, no association was observed between overall survival and each individual polymorphism in the GSTT1, GSTM1, SULT1A1, or UGT1A1gene. Individuals homozygous for the GSTP1105Val allele had a 63% reduced risk of decease (RR = 0.37, 95% CI = 0.16, 0.86) as compared with the 105Ile/105Ile genotype. Potential joint effects of all polymorphisms were evaluated by estimating RRs based on the number of variant genotypes in the SULT1A1, UGT1A1, GSTP1, GSTM1, and GSTT1 genes. The adjusted RRs for death were 1.30 (95% CI = 0.90, 1.87) for patients carrying 1 variant gene, 0.91 (95% CI = 0.64,1.30) for patients carrying 2 variant genes, 1.24 (95% CI = 0.82, 1.87) for patients carrying 3 variant genes, and 1.36 (95% CI = 0.55, 3.39) for patients carrying 4 or more variant genes, compared with those with none of these variant genotypes in these genes. These results do not support a strong effect of genetic polymorphisms in these phase II drug-metabolizing enzymes on breast cancer survival.

Genetic Polymorphisms in Selected Phase II Drug-Metabolizing Enzymes in Relation to Breast Cancer Survival